Drug Information

Drug General Information
Drug ID
D0UJ0D
Former ID
DNCL003634
Drug Name
ISIS-FGFR4Rx
Indication Obesity [ICD9: 278; ICD10:E66] Phase 2 [525236]
Company
ISIS pharmaceuticals
Target and Pathway
Target(s) FGF-4 receptor Target Info Modulator [543498]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
PANTHER Pathway FGF signaling pathway
Pathway Interaction Database FGF signaling pathway
Reactome PI3K Cascade
PIP3 activates AKT signaling
FGFR4 ligand binding and activation
Constitutive Signaling by Aberrant PI3K in Cancer
Phospholipase C-mediated cascade
FRS-mediated FGFR4 signaling
SHC-mediated cascade:FGFR4
PI-3K cascade:FGFR4
Negative regulation of FGFR4 signaling
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
PIP3 activates AKT signaling
Signaling by FGFR
References
Ref 525236ClinicalTrials.gov (NCT02476019) A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients.
Ref 543498(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.